RWJBarnabas Health, Rutgers open $225M cancer center
Elizabeth Gregerson / beckershospitalreview - On June 22, West Orange, N.J.-based RWJBarnabas Health and New Brunswick, N.J.-based Rutgers Cancer Institute opened the Melchiorre Cancer Center at Cooperman Barnabas Medical Center in Livingston, N.J. The cancer center cost $225 million, according to a …
AI Summary: Results presented at ASCO for daraxonrasib delivered practice‑changing evidence in pancreatic cancer, prompting clinicians to offer the drug off‑trial within weeks. The data generated excitement across conferences and clinical teams, fueling early adoption discussions and raising hopes for a tangible advance against a historically stubborn disease.
- ASCO shockwave: Daraxonrasib survival curve draws standing ovation (3)
- Competing KRAS strategies: zoldonrasib, HRS‑4642 and blood testing (4)
- Conference context: RAS momentum and expert reflections (5)
- Rapid off‑trial rollout and early patient access (4)
- All Other Stories
ASCO shockwave: Daraxonrasib survival curve draws standing ovation
Competing KRAS strategies: zoldonrasib, HRS‑4642 and blood testing
Conference context: RAS momentum and expert reflections
Rapid off‑trial rollout and early patient access
All Other Stories
FDA Approves Gilead’s Trodelvy, Alone and With Merck’s Keytruda, in First-Line Metastatic TNBC
oncodaily - Decision delivers the first ADC-based regimens for previously untreated triple-negative breast cancer across PD-L1 status, a PD-L1-positive Keytruda combination plus a monotherapy option for immunotherapy-ineligible patients. The U.S. Food and […]
AI Summary: The FDA approved sacituzumab govitecan (Trodelvy) as both monotherapy and in combination with pembrolizumab (Keytruda) for first-line treatment of metastatic triple‑negative breast cancer, expanding options for a hard-to-treat population. Regulators cited clinical benefit in appropriate patients, reshaping treatment sequencing and payer discussions.
FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC
esmo -
AI Summary: Regulators have approved datopotamab deruxtecan for patients with unresectable or metastatic triple‑negative breast cancer, offering a new targeted option where few exist. The decision follows trial evidence of meaningful anti‑tumor activity and expands the treatment toolkit for aggressive TNBC subtypes, with clinicians weighing sequencing and toxicity management.
Ashok Sebastian Komaranchath: Delighted to Speak at the 5th International Oncology Forum on 20–21 June 2026
oncodaily - Ashok Sebastian Komaranchath, Consultant Medical Oncology and Clinical Lead for Oncology Services at Burjeel Cancer Institute, Oman, shared on LinkedIn: “I was delighted to speak at the 5th International Oncology Forum […]
AI Summary: The FDA (and HHS) launched Operation TrialBlazer, an initiative to accelerate and modernize clinical development by streamlining trial design, data sharing and regulatory pathways. The program aims to reclaim trial competitiveness and reduce time‑to‑market, promising faster patient access — if stakeholders can agree on what “modernize” actually means.
Medical Journal Retracts Study Claiming Cancer Therapy Is More Effective When Given in the Morning
Rebecca Robbins / nytimes - In a notice flagging a series of problems with a clinical trial, the journal Nature Medicine said its editors “no longer have confidence in the integrity of the results.”
AI Summary: A high‑profile medical journal retracted a paper that claimed cancer immunotherapy is significantly more effective when administered in the morning. The reversal follows scrutiny over methods and data integrity, prompting clinicians to pause any scheduling changes until robust evidence actually materializes.
Bruce Levine: Ten-Year Outcomes Reinforce the Durability of CD19 CAR T-Cell Therapy
oncodaily - Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania, shared a post on X: “NEW – Ten-Year Outcomes after CAR T-Cell Therapy for […]
AI Summary: Long‑term data reveal that CD19 CAR‑T therapy produces durable remissions in a subset of B‑cell lymphoma patients, with ten‑year outcomes reinforcing the treatment's long‑term benefit for some. The findings bolster CAR‑T’s curative potential while underscoring the need to identify who will enjoy durable responses.